Wednesday, December 30, 2015

Xarelto Bellwether Trial Criteria Announced

Xarelto Drug Lawsuit

The selection of the bellwether trials in the Xarelto multidistrict litigation (MDL) are currently underway.

A case management order from U.S. District Judge Eldon Fallon dated Nov. 20, 2015 outlined the criteria for selecting these trials.

Several Xarelto lawsuits will now be chosen for inclusion in a bellwether discovery pool. These cases are generally chosen based on which appear to be most ready for trial.

Initially, the judge asked that both plaintiffs and defendants work together to determine the cases selected for the bellwether pool, however, when they were unable to agree on criteria for their selections, the Judge stepped forward to complete the task.

As requested, a total of 40 Xarelto cases will be chosen to include in the bellwether pool. At this time, plaintiffs and defendants will each select 10 cases, and the remaining cases will be randomly selected.

It has been announced by the judge as well that half of the selected cases will be from the Eastern District of Louisiana, while 7 will be from states selected by the defendants and 7 will be from states selected by the plaintiffs.

Additionally, 2 cases in the pool will be from Texas federal court and 4 will be from Mississippi federal court. These states chosen must have had at least 20 eligible cases filed concerning the pending litigation.

The quickly approaching status conference for the Xarelto MDL is set for December 21st, 2015. Judge Fallon has asked that parties involved get together between now and then in order to set the eligibility criteria for case selection and to plan case categories.

Additionally, they have been asked to plan selection for the initial 4 cases to go to trial. It is expected that the first trial dates for these cases may be between February and May of 2017.

At this time, the MDL includes over 2,800 Xarelto lawsuits alleging that defendants Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG neglected to provide an antidote for their anticoagulant drug and neglected to properly warn consumers of the significant dangers associated with Xarelto use.

Xarelto Lawsuit Allegations

The Xarelto lawsuits consolidated in the MDL all similarly allege that the new generation blood thinning drug can cause episodes of dangerous and sometimes fatal uncontrollable bleeding. Xarelto has become widely considered the most dangerous blood thinner on the market due to the fact that it has no corresponding antidote.

For someone taking a traditional blood thinner such as warfarin, however, there is an antidote available through vitamin K. If an individual taking a traditional blood thinner is injured and bleeding, doctors can treat them with vitamin K, reversing the medicine’s effects and successfully clotting their blood.

This is not the case with Xarelto.  This means that if a patient using Xarelto is injured and bleeds, physicians will be unable to get that patient’s blood to clot. In these instances, doctors have to resort to extreme life-saving measures such as blood transfusions.

If you or a loved one have suffered injuries including uncontrollable gastrointestinal bleeding from taking Xarelto you may be entitled to compensation.

The Xarelto Bleeding MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.

Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.

Learn More

Get Help – It’s Free

Join a Free Xarelto Class Action Lawsuit Investigation

If you or a loved one took Xarelto (rivaroxaban) and suffered injuries such as uncontrollable internal bleeding, gastrointestinal bleeding, hemorrhaging, deep vein thrombosis or pulmonary embolism, you may have a legal claim. See if you qualify by filling out the short form below.

An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.

  • First Name*
  • Last Name*
  • Street Address*
  • Apt. #
  • City*
  • State*
    AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
  • Zip Code*
  • Phone*
  • Email*
  • Which blood thinner did you or a loved one take at the time of the injury or injuries?*
    • Pradaxa
    • Xarelto
    • Unknown
    • Other
  • Please check the injuries suffered:*
    • Death

    • Gastrointestinal Bleeding

    • Other Internal Bleeding

    • Cerebral Hemorrhaging

    • Ischemic Stroke

    • Unsure

    • None

  • ¿Necesita un orador español?
    • Yes
    • No
  • Please enter any additional details you would like the staff reviewing your submission to know.*
  • I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
    • Yes

if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 35) {gformInitChosenFields(‘#input_35_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_35_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_35_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [35, 1]) } );

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

  • Email*
  • State*
    selectAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific


jQuery(document).ready(function($){gformInitSpinner( 5, ‘http://topclassactionscom.c.presscdn.com/wp-content/plugins/gravityforms/images/spinner.gif’ );jQuery(‘#gform_ajax_frame_5’).load( function(){var contents = jQuery(this).contents().find(‘*’).html();var is_postback = contents.indexOf(‘GF_AJAX_POSTBACK’) >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find(‘#gform_wrapper_5’);var is_confirmation = jQuery(this).contents().find(‘#gform_confirmation_wrapper_5’).length > 0;var is_redirect = contents.indexOf(‘gformRedirect(){‘) >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;if(is_form){jQuery(‘#gform_wrapper_5’).html(form_content.html());setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery(‘#gform_wrapper_5’).offset().top); }, 50 );if(window[‘gformInitDatepicker’]) {gformInitDatepicker();}if(window[‘gformInitPriceFields’]) {gformInitPriceFields();}var current_page = jQuery(‘#gform_source_page_number_5’).val();gformInitSpinner( 5, ‘http://topclassactionscom.c.presscdn.com/wp-content/plugins/gravityforms/images/spinner.gif’ );jQuery(document).trigger(‘gform_page_loaded’, [5, current_page]);window[‘gf_submitting_5’] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find(‘#gforms_confirmation_message_5’).html();if(!confirmation_content){confirmation_content = contents;}setTimeout(function(){jQuery(‘#gform_wrapper_5’).replaceWith(” + confirmation_content + ”);jQuery(document).scrollTop(jQuery(‘#gforms_confirmation_message_5’).offset().top);jQuery(document).trigger(‘gform_confirmation_loaded’, [5]);window[‘gf_submitting_5’] = false;}, 50);}else{jQuery(‘#gform_5’).append(contents);if(window[‘gformRedirect’]) {gformRedirect();}}jQuery(document).trigger(‘gform_post_render’, [5, current_page]);} );} ); if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 5) {gformInitChosenFields(‘#input_5_2′,’No results matched’);} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_5_2′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [5, 1]) } );

The post Xarelto Bellwether Trial Criteria Announced appeared first on Top Class Actions.

from http://topclassactions.com/lawsuit-settlements/lawsuit-news/254461-xarelto-bellwether-trial-criteria-announced/


No comments:

Post a Comment